Background
Phase 1b/2, multicenter, single-arm registration trial (FELIX, NCT04404660). N=127 adults (≥18) with R/R BCP-ALL; 94 in the pivotal efficacy cohort (≥2 prior lines or post-allo-HSCT relapse). Obecabtagene autoleucel (obe-cel, AUTO1; AUCATZYL) is a novel autologous 41BBζ anti-CD19 CAR-T utilizing an intermediate-affinity anti-CD19 binder (vs standard high-affinity FMC63), designed to reduce peak CAR-T expansion and improve CAR-T persistence while minimizing toxicity. FDA approved November 2024. Published NEJM 2024.
Interventions and follow up
Regimen: Obecabtagene autoleucel (obe-cel) 410 × 10⁶ CAR-T cells IV (split dose days 1 and 10) after fludarabine/cyclophosphamide lymphodepletion in adult R/R B-ALL
Primary endpoint: Complete remission or complete remission with partial hematologic recovery (CR/CRp) within 3 months
mFollow up: 20.3 months
Primary endpoint: Complete remission or complete remission with partial hematologic recovery (CR/CRp) within 3 months
mFollow up: 20.3 months
Results
CR/CRp within 3 months (primary, pivotal cohort N=94): 76.6% (72/94; 95% CI 66.6–84.8%)
MRD-negative among responders: 97%
mRFS (responders): Not reached at 20.3 months
12-month EFS: ~48%
12-month OS: ~65%
Grade ≥3 CRS (pivotal cohort): 2.4% (vs brexu-cel 24%)
Grade ≥3 ICANS: 7.1%
MRD-negative among responders: 97%
mRFS (responders): Not reached at 20.3 months
12-month EFS: ~48%
12-month OS: ~65%
Grade ≥3 CRS (pivotal cohort): 2.4% (vs brexu-cel 24%)
Grade ≥3 ICANS: 7.1%
Adverse events
CRS: Any-grade 74% (mostly grade 1–2); grade ≥3 only 2.4% — markedly lower severe CRS rate vs brexu-cel
Neurologic (ICANS): Any-grade 18%; grade ≥3 7.1%
Hematologic/infectious: Prolonged grade ≥3 cytopenias ~50%; grade ≥3 infections ~20%
Deaths/second malignancy: 4 treatment-related deaths; FDA 2024 boxed warning for secondary T-cell malignancy (class effect; no cases in FELIX at cutoff)
Neurologic (ICANS): Any-grade 18%; grade ≥3 7.1%
Hematologic/infectious: Prolonged grade ≥3 cytopenias ~50%; grade ≥3 infections ~20%
Deaths/second malignancy: 4 treatment-related deaths; FDA 2024 boxed warning for secondary T-cell malignancy (class effect; no cases in FELIX at cutoff)
Conclusions
Obe-cel achieved 76.6% CR/CRp with 97% MRD-negativity in heavily pretreated adult R/R B-ALL, with a markedly improved safety profile vs brexucabtagene autoleucel — grade ≥3 CRS of only 2.4% vs 24%. The intermediate-affinity anti-CD19 binder appears to deliver equivalent efficacy with substantially reduced cytokine-driven toxicity.
Key Limitations
Single-arm design without head-to-head comparator; cross-trial CRS comparison with brexu-cel is not formally randomized. Follow-up of 20.3 months is relatively short for assessing durability and late relapse. 12-month EFS of ~48% indicates frequent relapse despite favorable safety. Note: this entry is categorized cat3=CLL in the source database but describes a B-ALL trial — disease classification should be reviewed.
Clinical Context
FELIX supported the FDA approval (November 2024) of obecabtagene autoleucel for adults with R/R B-ALL; EMA review ongoing. ASCO and ESMO guidance recognize CD19 CAR-T as a standard option for adult R/R B-ALL, with obe-cel's low-toxicity profile making it attractive for patients at higher risk of CRS/ICANS and potentially outpatient administration.